Loading...
Loading...
DAWN| Name | Value |
|---|---|
| Revenues | 30.8M |
| Cost of Revenue | 2.9M |
| Gross Profit | 27.9M |
| Operating Expense | 68.9M |
| Operating I/L | -41.1M |
| Other Income/Expense | 5.1M |
| Interest Income | 5.1M |
| Pretax | -36.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -36.0M |
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in developing and commercializing targeted therapies for genetically defined cancers. Its lead product candidate, DAY101, is an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor currently in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2.
